In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinoloneFUJIKAWA, Katsuko; CHIBA, Megumi; TANAKA, Mayumi et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 7, pp 3040-3045, issn 0066-4804, 6 p.Article

Antistaphylococcal activity of DX-619, a new Des-F(6)-quinolone, compared to those of other agentsBOGDANOVICH, Tatiana; ESEL, Duygu; KELLY, Linda M et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 8, pp 3325-3333, issn 0066-4804, 9 p.Article

Origin of plasmid-mediated quinolone resistance determinant QnrAPOIREL, Laurent; RODRIGUEZ-MARTINEZ, Jose-Manuel; MAMMERI, Hedi et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 8, pp 3523-3525, issn 0066-4804, 3 p.Article

In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinoloneTANAKA, Kaori; MIKAMO, Hiroshige; NAKAO, Kenichi et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 11, pp 3908-3913, issn 0066-4804, 6 p.Article

Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo SimulationLANDERSDORFER, Cornelia B; KINZIG, Martina; HENNIG, Friedrich F et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 2074-2081, issn 0066-4804, 8 p.Article

Association of plasmid-mediated quinolone resistance with extended-spectrum β-lactamase VEB-1POIREL, Laurent; VAN DE LOO, Marc; MAMMERI, Hedi et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 7, pp 3091-3094, issn 0066-4804, 4 p.Article

The fluorescence characteristic of the yttrium-norfloxacin system and its analytical applicationYUNXIAO HAN; XIA WU; JINGHE YANG et al.Journal of pharmaceutical and biomedical analysis. 2005, Vol 38, Num 3, pp 528-531, issn 0731-7085, 4 p.Article

The quinolones : Past, present, and futureANDRIOLE, Vincent T.Clinical infectious diseases. 2005, Vol 41, pp S113-S119, issn 1058-4838, SUP2Article

Diffusion of levofloxacin into bone and synovial tissuesRIMMELE, T; BOSELLI, E; BREILH, D et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 53, Num 3, pp 533-535, issn 0305-7453, 3 p.Article

Enquête rétrospective sur l'utilisation des fluoroquinolones en pédiatrie = Retrospective survey of fluoroquinolone use in childrenPADENTE-KHAYAT, A; VAUZELLE-KERVROEDAN, F; D'ATHIS, P et al.Archives de pédiatrie (Paris). 1998, Vol 5, Num 5, pp 484-488, issn 0929-693XConference Paper

Fluoroquinolone toxicities : an updateLIETMAN, P. S.Drugs (Basel). 1995, Vol 49, pp 159-163, issn 0012-6667, SUP2Conference Paper

Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1XIAOGANG XU; SHI WU; XINYU YE et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 11, pp 4105-4110, issn 0066-4804, 6 p.Article

Ciprofloxacin-induced anaphylactoid reactionKOTHUR, Kavitha; SINGH, Meenu; DAYAL, Devi et al.European journal of pediatrics. 2006, Vol 165, Num 8, pp 573-574, issn 0340-6199, 2 p.Article

qnrB, another plasmid-mediated gene for quinolone resistanceJACOBY, George A; WALSH, Kelley E; MILLS, Debra M et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 4, pp 1178-1182, issn 0066-4804, 5 p.Article

Dual targeting of topoisomerase IV and gyrase to reduce mutant selection : Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacinSTRAHILEVITZ, Jacob; HOOPER, David C.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 5, pp 1949-1956, issn 0066-4804, 8 p.Article

New milestones achieved in fluoroquinolone safetyTILLOTSON, Glenn S; RYBAK, Michael J.Pharmacotherapy. 2001, Vol 21, Num 3, pp 358-360, issn 0277-0008Conference Paper

Drug utilization reviews of oral quinolone, cephalosporin, and macrolide use in nonacute care : A systematic reviewSPOONER, C. H; PICKARD, A. S; MENON, D et al.Clinical therapeutics. 1999, Vol 21, Num 11, pp 1951-1972, issn 0149-2918Article

Mutational Analysis of Quinolone Resistance Protein QnrB1JACOBY, George A; CORCORAN, Marian A; MILLS, Debra M et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5733-5736, issn 0066-4804, 4 p.Article

In Vitro Antituberculosis Activities of ACH-702, a Novel Isothiazoloquinolone, against Quinolone-Susceptible and Quinolone-Resistant IsolatesPUCCI, Michael J; ACKERMAN, Maria; THANASSI, Jane A et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 8, pp 3478-3480, issn 0066-4804, 3 p.Article

Quinolone-Mediated Bacterial DeathDRIICA, Karl; MALIK, Muhammad; KERNS, Robert J et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 2, pp 385-392, issn 0066-4804, 8 p.Article

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT StudiesBLOOMFIELD, D. M; KOST, J. T; GHOSH, K et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 4, pp 475-480, issn 0009-9236, 6 p.Article

Effect of anaerobic growth on quinolone lethality with Escherichia coliMALIK, Muhammad; HUSSAIN, Syed; DRLICA, Karl et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 1, pp 28-34, issn 0066-4804, 7 p.Article

Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agentsKOSOWSKA-SHICK, Klaudia; CREDITO, Kim; PANKUCH, Glenn A et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 6, pp 2064-2071, issn 0066-4804, 8 p.Article

A 10-day levofloxacin-based triple therapy in patients who have failed two eradication coursesGATTA, L; ZULLO, A; MORINI, S et al.Alimentary pharmacology & therapeutics. 2005, Vol 22, Num 1, pp 45-49, issn 0269-2813, 5 p.Article

Protonation equilibrium and lipophilicity of moxifloxacinLANGLOIS, Marie-Hélène; MONTAGUT, Martine; DUBOST, Jean-Pierre et al.Journal of pharmaceutical and biomedical analysis. 2005, Vol 37, Num 2, pp 389-393, issn 0731-7085, 5 p.Article